Anna Bratulic

Bristol Myers Squibb is adding new patients to its Phase III

The FDA has pushed back by about a week its expedited reassessment of a partia...

 

Sangamo Therapeutics said it plans to file its Fabry disease gene therapy isar...

Jazz Pharmaceuticals will seek expanded US approval for its HER2-directed bisp...

The FDA on Friday approved a more restrictive label for Sarepta Therapeutics' ...

Fresh off the high-profile bidding war that saw

Barely a month after joining Merck & Co. through a

Eli Lilly has struck a deal worth potentially more than $475 million with MeiraGTx to license a gene therapy that allows children born blind to gain sight. The agreement grants Lilly exc...

Detailed results from the VESALIUS-CV trial, unveiled Saturday at the American...